Adheron Therapeutics

4 articles about Adheron Therapeutics

• 

  New Report Highlights Potential of Largely Untapped Drug Development Target

  5/24/2022

  A new report in La Merie Publishing describes and analyzes cadherin 17 as a promising target for drug development, which has largely gone unexploited.
• 

  With Q3 and 2018 Looking Good, Roche Abandons 8 Pipeline Products

  10/17/2018

  Overall, the Swiss-based Roche announced a group sales increase of 7 percent, with the Pharmaceuticals Division up 7 percent, largely driven by sales of Ocrevus, Perjeta, Alecensa and Tecentriq.

• Despite Concerns About Market Volatility, Roche Acquires Adheron for $580 Million

  10/12/2015

• Adheron Therapeutics Announces Favorable Phase 1 Clinical Trial Results

  1/8/2014